Beam Therapeutics Q4 Loss Shrinks to $0.10, Revenue Soars 9x to $114M
Beam Therapeutics reported Q4 loss of $0.10 per share vs $0.99 loss estimate and revenue of $114.11M vs $12.57M consensus, driving shares up 13.5%. The company secured a $500M senior secured credit facility, plans a 2026 IND for BEAM-304 in phenylketonuria and expects cash runway into mid-2029.
1. Q4 Financial Outperformance
Beam delivered a fourth-quarter loss of $0.10 per share, far better than the $0.99 consensus loss estimate, while revenue climbed to $114.11 million versus $12.57 million expected, reflecting strong adoption of base editing proof‐of‐concept data.
2. Strategic $500M Financing
The company announced a $500 million senior secured credit facility, including $100 million funded at close, $300 million available upon clinical, regulatory and commercial milestones and an additional $100 million at Beam’s option during the seven-year term.
3. BEAM-304 Phenylketonuria Program
Beam expanded its liver-targeted genetic disease franchise with BEAM-304 for phenylketonuria and intends to file an IND with the FDA in 2026 following completion of pre-IND activities, targeting a high-value rare disease.
4. Cash Runway and Development Outlook
Supported by non-dilutive financing, Beam projects cash runway into mid-2029, funding the anticipated launch of risto-cel in sickle cell disease, execution of the BEAM-302 pivotal plan in AATD and clinical proof-of-concept for BEAM-304.